Shanghai Junshi Biosciences Co., Ltd. provided earnings guidance for the period ended 31 December 2021. It is estimated that the operating revenue for 2021 would be approximately RMB 4,014 million, representing an increase of approximately RMB 2,419.1034 million compared with the same period of the previous year or a year-on-year increase of approximately 151.68%. It is estimated that the net loss attributable to the owners of the parent company for 2021 would be approximately RMB 736 million, representing a decrease in loss of approximately RMB 932.6068 million compared with the same period of the previous year or a year-on-year decrease in loss of approximately 55.89%.

It is estimated that the net loss attributable to the owners of the parent company after deducting non-recurring gains and losses for 2021 would be approximately RMB 921 million, representing a decrease in loss of approximately RMB 787.8250 million compared with the same period of the previous year or a year-on-year decrease in loss of approximately 46.10%.